» Articles » PMID: 34349622

From Junk to Function: LncRNAs in CNS Health and Disease

Overview
Specialty Molecular Biology
Date 2021 Aug 5
PMID 34349622
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Recent advances in RNA sequencing technologies helped to uncover the existence of tens of thousands of long non-coding RNAs (lncRNAs) that arise from the dark matter of the genome. These lncRNAs were originally thought to be transcriptional noise but an increasing number of studies demonstrate that these transcripts can modulate protein-coding gene expression by a wide variety of transcriptional and post-transcriptional mechanisms. The spatiotemporal regulation of lncRNA expression is particularly evident in the central nervous system, suggesting that they may directly contribute to specific brain processes, including neurogenesis and cellular homeostasis. Not surprisingly, lncRNAs are therefore gaining attention as putative novel therapeutic targets for disorders of the brain. In this review, we summarize the recent insights into the functions of lncRNAs in the brain, their role in neuronal maintenance, and their potential contribution to disease. We conclude this review by postulating how these RNA molecules can be targeted for the treatment of yet incurable neurological disorders.

Citing Articles

LncRNAs Orchestrating Neuroinflammation: A Comprehensive Review.

Esmaeili A, Yazdanpanah N, Rezaei N Cell Mol Neurobiol. 2025; 45(1):21.

PMID: 40056236 PMC: 11890384. DOI: 10.1007/s10571-025-01538-0.


The double-edged sword of lncRNAs in rheumatoid arthritis: from controlling the disease to its progress.

Liu Z, Xu H, Chen Z Clin Exp Med. 2025; 25(1):76.

PMID: 40053152 PMC: 11889058. DOI: 10.1007/s10238-025-01567-5.


Deciphering the epigenetic role of long non-coding RNAs in mood disorders: Focus on human brain studies.

Roy B, Verma A, Funahashi Y, Dwivedi Y Clin Transl Med. 2025; 15(3):e70135.

PMID: 40038891 PMC: 11879898. DOI: 10.1002/ctm2.70135.


Advancements in genetic research and RNA therapy strategies for amyotrophic lateral sclerosis (ALS): current progress and future prospects.

Ruffo P, Traynor B, Conforti F J Neurol. 2025; 272(3):233.

PMID: 40009238 PMC: 11865122. DOI: 10.1007/s00415-025-12975-8.


lncRNA PART1 improves sevoflurane-induced impairments in learning and cognitive function by regulating miR-16-5p expression and reducing neuroinflammation.

Lin Y, Yu W, Yang W, Wang N, Zhang Q, Guan Y Toxicol Res (Camb). 2025; 14(1):tfaf009.

PMID: 39872305 PMC: 11766745. DOI: 10.1093/toxres/tfaf009.


References
1.
Wahlestedt C . Targeting long non-coding RNA to therapeutically upregulate gene expression. Nat Rev Drug Discov. 2013; 12(6):433-46. DOI: 10.1038/nrd4018. View

2.
Wang X, Goodrich K, Gooding A, Naeem H, Archer S, Paucek R . Targeting of Polycomb Repressive Complex 2 to RNA by Short Repeats of Consecutive Guanines. Mol Cell. 2017; 65(6):1056-1067.e5. DOI: 10.1016/j.molcel.2017.02.003. View

3.
Tak Y, Farnham P . Making sense of GWAS: using epigenomics and genome engineering to understand the functional relevance of SNPs in non-coding regions of the human genome. Epigenetics Chromatin. 2016; 8:57. PMC: 4696349. DOI: 10.1186/s13072-015-0050-4. View

4.
Luo T, Liu P, Wang X, Li L, Zhao L, Huang J . Effect of the autism-associated lncRNA Shank2-AS on architecture and growth of neurons. J Cell Biochem. 2018; 120(2):1754-1762. DOI: 10.1002/jcb.27471. View

5.
Gutschner T, Baas M, Diederichs S . Noncoding RNA gene silencing through genomic integration of RNA destabilizing elements using zinc finger nucleases. Genome Res. 2011; 21(11):1944-54. PMC: 3205578. DOI: 10.1101/gr.122358.111. View